FGF23 treatment led to changes in renal NaPi-IIa and Vdr protein expression.
Larissa Kägi
Carla Bettoni
Eva M. Pastor-Arroyo
Udo Schnitzbauer
Nati Hernando
Carsten A. Wagner
10.1371/journal.pone.0195427.g006
https://plos.figshare.com/articles/figure/FGF23_treatment_led_to_changes_in_renal_NaPi-IIa_and_Vdr_protein_expression_/6283667
<p>Representative western blots of total renal protein homogenates from mice injected with either vehicle (Ctrl) or recombinant human FGF23 (rhFGF23) once a day for two consecutive days using antibodies against NaPi-IIa <b>(A)</b>, full length Klotho <b>(B)</b>, Cyp24a1 <b>(C)</b> and Vdr <b>(D)</b>. The proteins of interest are shown in the top panels, whereas the corresponding β-actin signal is shown in the bottom image. Densitometric quantification was normalized to the corresponding β-actin values. Bar graphs represent mean ± SD (n = 5-6/group) of the normalized values and data was analyzed by unpaired student’s t-test with significant p values indicated as: * p ≤ 0.05.</p>
2018-05-17 08:17:15
2 D 3
fibroblast growth factor 23
vitamin D metabolizing enzymes
2 D 3 synthesis
OH
Pi
2 D 3 Background
extrarenal tissues
Cyp 24a
25- hydroxylases CYP 2R
vitamin D hydroxylases
27A
27B
expression
2 D 3 treatment
24- hydroxylase CYP 24A catalyzes
vitamin D receptor VDR
cytochrome P 450
FGF 23
PTH